MITOFORGE™: Precision Intracellular Delivery™ Platform

Our new website is coming soon.

ViCardia Therapeutics is a clinical-stage biopharmaceutical company developing MitoForge™, a modular, peptide-directed delivery platform designed to restore mitochondrial function in chronic and rare diseases.

Existing therapies treat symptoms. We’re built to restore cellular health.

Focus areas: Cardiovascular · Neurodegeneration · Metabolic disease · Rare genetic mitochondrial disorders · Cardio-renal syndrome

Founded 2018 · Headquarters San Francisco

Contact us
ViCardia Therapeutics, Inc.
530 Bush Street, Suite 802
San Francisco, CA 94108
[email address – please provide]

© 2026 ViCardia Therapeutics, Inc. All Rights Reserved.
MitoForge™ and Precision Intracellular Delivery™ are trademarks of ViCardia Therapeutics, Inc.